[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back TREATMENTS
Isocitrate Dehydrogenase-2 (IDH2) Inhibitor
Enasidenib is an oral, selective, mutant IDH2 inhibitor approved for IDH2-mutated (mIDH2) relapsed/refractory acute myeloid leukemia.
Enasidenib (Idhifa®) VIEW TREATMENT
newsletter icon

Get the latest thought leadership on your Acute Myeloid Leukemia delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Acute Myeloid Leukemia Sponsors:

Abbvie
Astellas Pharma
Servier

Follow Us

facebook instagram youtube

Education

News Articles My Journal University Expert Webinars Find a Specialist HealthTree Podcast

Community

Connect Chapters Coach Moves All Events

Cure Hub

HealthTree Cure Hub Find Side Effects Solutions See Tracked Labs Connect Medical Records Treatment Options Twin Machine Clinical Trial Finder

Get Involved

Create a fundraiser Tribute Donate Patient Surveys & Studies Connect Medical Records

About us

Our Story

Need Help?

Contact Us FAQ & Help Center 1-800-709-1113

Legal Info

Terms of Use Privacy Policy

Charity Navigator https://www.guidestar.org/profile/45-5354811

HealthTree Foundation is a qualified 501(c)(3) tax-exempt organization.

Copyright © 2024 HealthTree Foundation. All rights reserved.

Tax ID 45-5354811